{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000043","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.786120+00:00","generated_at":"2026-06-16T02:18:10.379928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Q1 GAAP net loss $76.6M; INGREZZA sales $410M (+36% YoY)","bullets":["INGREZZA net sales $410M, up 36% YoY; guidance reiterated at $1.67-1.77B for FY2023.","GAAP net loss $76.6M ($0.79 loss per share) vs $13.9M income in Q1 2022.","Non-GAAP net loss $49.5M ($0.51 loss per share) vs $29.7M income in prior year.","Recorded $143.9M acquired IPR&D expense for Voyager gene therapy collaboration.","Valbenazine PDUFA for Huntington chorea set for Aug 20, 2023; top-line data from crinecerfont expected early Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000043","json":"https://secwatch.observer/filing/0000914475-23-000043.json","markdown":"https://secwatch.observer/filing/0000914475-23-000043.md","text":"https://secwatch.observer/filing/0000914475-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000043/0000914475-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000043/nbix-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:18:10.379928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}